Ace inhibitors and arbs comparison
Pro Research Analysisby 
Searched over 200M research papers
Comparative Effectiveness of ACE Inhibitors and ARBs for Hypertension and Heart Failure
Multiple studies consistently show that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are equally effective in lowering blood pressure and managing heart failure symptoms. Both drug classes are recommended as first-line treatments for hypertension and have similar efficacy in reducing cardiovascular events, such as heart attack, stroke, and heart failure, in patients with or without existing heart failure 1245+4 MORE.
Safety and Tolerability: Side Effects of ACE Inhibitors vs. ARBs
While both ACE inhibitors and ARBs are effective, ARBs have a better safety and tolerability profile. ACE inhibitors are more likely to cause side effects such as cough and angioedema, which are related to the accumulation of bradykinin. ARBs, which do not affect bradykinin, have a lower risk of these side effects and result in fewer withdrawals due to adverse events 1478+1 MORE. This improved tolerability makes ARBs a preferred option for patients who experience side effects with ACE inhibitors.
Cost-Effectiveness in Heart Failure Management
From a healthcare system perspective, ACE inhibitors are generally more cost-effective than ARBs, especially in patients with severe heart failure. While both drug classes offer similar health outcomes, ACE inhibitors tend to have lower overall costs and slightly higher quality-adjusted life years. However, for most patients, especially those intolerant to ACE inhibitors, ARBs remain a reasonable alternative .
Impact on Insulin Sensitivity and Metabolic Outcomes
When comparing effects on insulin sensitivity in hypertensive patients, there is little difference between ACE inhibitors and ARBs for most measures. However, ACE inhibitors may offer a slight advantage in improving certain insulin sensitivity markers, particularly in long-term use and among patients with diabetes. Still, these differences are small and may not be clinically significant for most patients .
Practice Guidelines and Clinical Considerations
Current clinical guidelines recommend both ACE inhibitors and ARBs as first-line options for hypertension and heart failure. Both classes also provide added benefits for patients with comorbidities such as diabetes, chronic kidney disease, and a history of stroke or myocardial infarction. The choice between the two often depends on individual patient tolerance, side effect profiles, and, in some cases, cost considerations 679.
Conclusion
ACE inhibitors and ARBs are equally effective for managing hypertension and heart failure, with no significant differences in major cardiovascular outcomes. ARBs are better tolerated, with fewer side effects like cough and angioedema, making them a preferred choice for many patients. ACE inhibitors may be more cost-effective in some settings, but both drug classes are supported by guidelines as first-line therapies. The decision between ACE inhibitors and ARBs should be individualized based on patient characteristics, side effect risk, and cost.
Sources and full results
Most relevant research papers on this topic